Taysha Gene Therapies, Inc. TSHA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s accounts payable?
- Taysha Gene Therapies, Inc. (TSHA) reported accounts payable of $4.56M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s accounts payable changed year-over-year?
- Taysha Gene Therapies, Inc.'s accounts payable increased by 5.5% year-over-year, from $4.33M to $4.56M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s accounts payable has grown at a -18.7% compound annual growth rate (CAGR), from $54.25M to $23.75M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.